Pharmacological management of connective tissue disease-associated pulmonary arterial hypertension-Reference-Cited by-同舟云学术

Pharmacological management of connective tissue disease-associated pulmonary arterial hypertension

Published:2023-10-30 Issue:18 Volume:24 Page:2101-2115
ISSN:1465-6566
Container-title:Expert Opinion on Pharmacotherapy
language:en
Short-container-title:Expert Opinion on Pharmacotherapy

Author:

Kularatne Mithum¹^ORCID,Boucly Athénaïs²³⁴^ORCID,Savale Laurent²³⁴^ORCID,Solinas Sabina²³⁴,Cheron Céline²³⁴,Roche Anne²³⁴,Jevnikar Mitja²³⁴^ORCID,Jaïs Xavier²³⁴^ORCID,Montani David²³⁴^ORCID,Humbert Marc²³⁴^ORCID,Sitbon Olivier²³⁴^ORCID

Affiliation:

1. Division of Respiratory Medicine, Department of Medicine, University of Calgary, Calgary, Canada

2. Faculty of Medicine, Université Paris-Saclay, Le Kremlin-Bicêtre, France

3. INSERM UMR_S 999 Pulmonary Hypertension: Pathophysiology and Novel Therapies, Le Kremlin-Bicêtre, France

4. AP-HP, Department of Respiratory and Intensive Care Medicine, Pulmonary Hypertension National Referral Centre, DMU 5 Thorinno, Hôpital Bicêtre, Le Kremlin-Bicêtre, France

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Pharmacology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14656566.2023.2273395

Reference121 articles.

1. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension

2. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension

3. Pathology and pathobiology of pulmonary hypertension: state of the art and research perspectives

4. Epidemiology and treatment of pulmonary arterial hypertension

5. Characterization of Connective Tissue Disease-Associated Pulmonary Arterial Hypertension From REVEAL